Key findings regarding androgen-targeted therapy resistance:
Antiandrogen treatment can cause stromal cell reprogramming, leading to SPP1+ myCAFs (myofibroblastic cancer-associated fibroblasts) that create a microenvironment resistant to androgen deprivation therapy. Androinz.Reverse_Treatment.1.var
Based on recent research into prostate cancer treatment, remains a key target, but therapy resistance (specifically, castration-resistant prostate cancer, or CRPC) is a major challenge. Research highlights that, while standard treatments like enzalutamide or abiraterone are used, tumor resistance often emerges through the adaptation of AR variants (e.g., AR-V7 , ARv567es ). remains a key target